keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer progesterone

keyword
https://www.readbyqxmd.com/read/28717716/breast-cancer-and-african-ancestry-lessons-learned-at-the-10-year-anniversary-of-the-ghana-michigan-research-partnership-and-international-breast-registry
#1
Evelyn Jiagge, Joseph Kwaku Oppong, Jessica Bensenhaver, Francis Aitpillah, Kofi Gyan, Ishmael Kyei, Ernest Osei-Bonsu, Ernest Adjei, Michael Ohene-Yeboah, Kathy Toy, Karen Eubanks Jackson, Marian Akpaloo, Dorcas Acheampong, Beatrice Antwi, Faustina Obeng Agyeman, Zainab Alhassan, Linda Ahenkorah Fondjo, Osei Owusu-Afriyie, Robert Newman Brewer, Amma Gyamfuah, Barbara Salem, Timothy Johnson, Max Wicha, Sofia Merajver, Celina Kleer, Judy Pang, Emmanuel Amankwaa-Frempong, Azadeh Stark, Francis Abantanga, Lisa Newman, Baffour Awuah
Women with African ancestry in western, sub-Saharan Africa and in the United States represent a population subset facing an increased risk of being diagnosed with biologically aggressive phenotypes of breast cancer that are negative for the estrogen receptor, the progesterone receptor, and the HER2/neu marker. These tumors are commonly referred to as triple-negative breast cancer. Disparities in breast cancer incidence and outcome related to racial or ethnic identity motivated the establishment of the International Breast Registry, on the basis of partnerships between the Komfo Anokye Teaching Hospital in Kumasi, Ghana, the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, and the Henry Ford Health System in Detroit, Michigan...
October 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717401/novel-therapeutic-strategies-in-the-treatment-of-triple-negative-breast-cancer
#2
REVIEW
Karima Oualla, Heba M El-Zawahry, Banu Arun, James M Reuben, Wendy A Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T Ueno, Tamer M Fouad
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels...
July 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28714765/comparison-of-estrogen-and-progesterone-receptor-antibody-reagents-using-proficiency-testing-data
#3
Megan L Troxell, Thomas Long, Jason L Hornick, Abiy B Ambaye, Kristin C Jensen
CONTEXT: - Immunohistochemical analysis of estrogen receptor (ER) and progesterone receptor (PgR) expression in breast cancer is the current standard of care and directly determines therapy. In 2010 the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) published guidelines for ER and PgR predictive testing, encompassing preanalytic, analytic, postanalytic factors; antibody validation; and proficiency testing. OBJECTIVE: - To compare the performance of different antibody reagents for ER and PgR immunohistochemical analysis by using CAP proficiency testing data...
July 17, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28713912/progesterone-suppresses-triple-negative-breast-cancer-growth-and-metastasis-to-the-brain-via-membrane-progesterone-receptor%C3%A2-%C3%AE
#4
Li Zhou, Wei Zhou, Hongwei Zhang, Yan Hu, Lei Yu, Yufei Zhang, Yanli Zhang, Shuang Wang, Peng Wang, Wei Xia
Progesterone plays an important role in mammary epithelial cell proliferation and differentiation. Evidence from experimental and clinical studies indicates that progesterone is a risk factor for breast cancer under certain conditions through binding nuclear progesterone receptor (PR). These mechanisms, however, are not applicable to triple-negative breast cancer (TNBC) due to the lack of PR in these cancers. In this study, we demonstrate that membrane progesterone receptor α (mPRα) is expressed in TNBC tissues and the expression level of mPRα is negatively associated with the TNM stage...
July 7, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#5
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28701332/circulating-rankl-and-rankl-opg-and-breast-cancer-risk-by-er-and-pr-subtype-results-from-the-epic-cohort
#6
Danja Sarink, Helena Schock, Theron Johnson, Kim Overvad, Marianne Holm, Anne Tjonneland, Marie-Christine Boutron-Ruault, Mathilde His, Marina Kvaskoff, Heiner Boeing, Pagona Lagiou, Eleni-Maria Papatesta, Antonia Trichopoulou, Domenico Palli, Valeria Pala, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, H B As Bueno-de-Mesquita, Carla H van Gils, Petra H Peeters, Elisabete Weiderpass, Antonio Agudo, Maria-Jose Sanchez, Maria-Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, Kay-Tee Khaw, Ruth C Travis, Laure Dossus, Marc J Gunter, Sabina Rinaldi, Melissa A Merritt, Elio Riboli, Rudolf Kaaks, Renee T Fortner
Receptor activator of nuclear factor kappa-B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. <p>A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort...
July 12, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28701032/bcl2-regulation-according-to-molecular-subtype-of-breast-cancer-by-analysis-of-the-cancer-genome-atlas-database
#7
Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi
Purpose: We investigated BCL2 regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database. Materials and Methods: We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data...
July 4, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28701017/high-level-of-progesteron-receptor-membrane-component-1-pgrmc-1-in-tissue-of-breast-cancer-patients-is-associated-with-worse-response-to-anthracycline-based-neoadjuvant-therapy
#8
Marina Willibald, Isabel Wurster, Christoph Meisner, Ulrich Vogel, Harald Seeger, Alfred O Mueck, Tanja Fehm, Hans Neubauer
PGRMC1 is known to be highly expressed in breast cancer tissue and is associated with chemoresistance in breast cancer cells. However, its role in breast cancer signaling is not fully understood yet. In the present study, the expression status of PGRMC1 and its phosphorylated version (pPGRMC1) in breast cancer tissue and surrounding stroma before and after neoadjuvant therapy was examined to find a possible association to therapy response. Tissue biopsies of 69 breast cancer patients were analyzed by immunohistochemistry for expression levels of PGRMC1 and pPGRMC1...
July 12, 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28697743/integrative-analysis-of-copy-number-and-gene-expression-in-breast-cancer-using-formalin-fixed-paraffin-embedded-core-biopsy-tissue-a-feasibility-study
#9
Mahesh Iddawela, Oscar Rueda, Jenny Eremin, Oleg Eremin, Jed Cowley, Helena M Earl, Carlos Caldas
BACKGROUND: An absence of reliable molecular markers has hampered individualised breast cancer treatments, and a major limitation for translational research is the lack of fresh tissue. There are, however, abundant banks of formalin-fixed paraffin-embedded (FFPE) tissue. This study evaluated two platforms available for the analysis of DNA copy number and gene expression using FFPE samples. METHODS: The cDNA-mediated annealing, selection, extension, and ligation assay (DASL™) has been developed for gene expression analysis and the Molecular Inversion Probes assay (Oncoscan™), were used for copy number analysis using FFPE tissues...
July 11, 2017: BMC Genomics
https://www.readbyqxmd.com/read/28697417/tumor-characteristics-and-family-history-in-relation-to-mammographic-density-and-breast-cancer-the-french-e3n-cohort
#10
Gertraud Maskarinec, Laureen Dartois, Suzette Delaloge, John Hopper, Françoise Clavel-Chapelon, Laura Baglietto
BACKGROUND: Mammographic density is a known heritable risk factor for breast cancer, but reports how tumor characteristics and family history may modify this association are inconsistent. METHODS: Dense and total breast areas were assessed using Cumulus™ from pre-diagnostic mammograms for 820 invasive breast cancer cases and 820 matched controls nested within the French E3N cohort study. To allow comparisons across models, percent mammographic density (PMD) was standardized to the distribution of the controls...
July 8, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28696357/myc-driven-pathways-in-breast-cancer-subtypes
#11
REVIEW
Yassi Fallah, Janetta Brundage, Paul Allegakoen, Ayesha N Shajahan-Haq
The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors...
July 11, 2017: Biomolecules
https://www.readbyqxmd.com/read/28693914/targeting-progesterone-metabolism-in-breast-cancer-with-l-proline-derived-new-14-azasteroids
#12
Jyotsana Singh, Ritesh Singh, Preeti Gupta, Smita Rai, Asha Ganesher, Preethi Badrinarayan, G Narahari Sastry, Rituraj Konwar, Gautam Panda
Breast cancer cell proliferation is promoted by a variety of mitogenic signals. Classically estrogen is considered as most predominant mitogenic signal in hormone-dependent breast cancer and progesterone is primarily considered to have protective effect. However, it is suggested that some progesterone metabolite may promote breast cancer and progesterone metabolites like 5α-pregnane and 4-pregnene could serve as regulators of estrogen-responsiveness of breast cancer cells. Here, we estimated the potential of alternate targeting of breast cancer via progesterone signalling...
June 19, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/28693495/an-agent-based-model-of-triple-negative-breast-cancer-the-interplay-between-chemokine-receptor-ccr5-expression-cancer-stem-cells-and-hypoxia
#13
Kerri-Ann Norton, Travis Wallace, Niranjan B Pandey, Aleksander S Popel
BACKGROUND: Triple-negative breast cancer lacks estrogen, progesterone, and HER2 receptors and is thus not possible to treat with targeted therapies for these receptors. Therefore, a greater understanding of triple-negative breast cancer is necessary for the treatment of this cancer type. In previous work from our laboratory, we found that chemokine ligand-receptor CCL5-CCR5 axis is important for the metastasis of human triple-negative breast cancer cell MDA-MB-231 to the lymph nodes and lungs, in a mouse xenograft model...
July 11, 2017: BMC Systems Biology
https://www.readbyqxmd.com/read/28693277/curcumol-triggers-apoptosis-of-p53-mutant-triple-negative-human-breast-cancer-mda-mb-231-cells-via-activation-of-p73-and-puma
#14
Lanzhen Huang, Ang Li, Guanzhen Liao, Feicheng Yang, Jing Yang, Xu Chen, Xiaoshan Jiang
Triple-negative breast cancer (TNBC; estrogen receptor-negative, progesterone receptor-negative and Her-2-negative) is often accompanied by a higher frequency of p53 gene mutations. Therefore, TNBC is challenging to treat due to a lack of biological targets and a poor sensitivity to conventional therapies. Curcumol is a monomer composition isolated from the ethanol extracts of Curcuma wenyujin, a Chinese medicinal herb traditionally used as a cancer remedy. Previous studies have revealed that curcumol is able to block proliferation in various human tumor cell lines...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28692125/steroid-metabolism-gene-polymorphisms-and-their-implications-on-breast-and-ovarian-cancer-prognosis
#15
E V W Dos Santos, L N R Alves, I D Louro
A role for estrogen in the etiology of breast and ovarian cancers has been suggested; therefore, genetic polymorphisms in steroid metabolism genes could be involved in the carcinogenesis of these tumors. We have aimed to investigate the role of GSTP1 and CYP17 polymorphisms and their correlation with MSI (microsatellite instability) and LOH (loss of heterozygosity) in AR, ERβ and CYP19 genes in women from Espírito Santo State, Brazil. The study population consisted of 107 female breast and 24 ovarian tumors...
July 6, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28692043/cross-talk-between-progesterone-receptors-and-retinoic-acid-receptors-in-regulation-of-cytokeratin-5-positive-breast-cancer-cells
#16
L M Fettig, O McGinn, J Finlay-Schultz, D V LaBarbera, S K Nordeen, C A Sartorius
Half of estrogen receptor-positive breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy resistant and exhibit increased cancer stem cell (CSC) properties. We and others have demonstrated that progesterone (P4) increases CK5+ breast cancer cells. We previously discovered that retinoids block P4 induction of CK5+ cells. Here we investigated the mechanisms by which progesterone receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity...
July 10, 2017: Oncogene
https://www.readbyqxmd.com/read/28690659/chronic-myeloid-leukemia-with-a-complex-variant-ph-translocation-that-develops-in-breast-carcinoma-postchemotherapy-a-rare-but-treatable-entity
#17
Gargi Tikku, Monica Jain, Pragya Shukla
We report a case of chronic myeloid leukemia (CML) that developed after postoperative chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) for breast cancer. A 55-year-old woman was diagnosed with invasive ductal carcinoma which was treated with a modified radical mastectomy followed by six cycles of CAF chemotherapy. Nine years later, she developed CML and locoregional recurrence. Her breast recurrence showed strong estrogen receptor, weak progesterone receptor and strong human epidermal growth factor 2 (score 3+) expression...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690653/high-histologic-grade-and-high-ki-67-expression-predict-phenotypic-alterations-in-node-metastasis-in-primary-breast-cancers
#18
Pablo Mandó, Manglio Rizzo, Constanza Perez de la Puente, Mercedes Maino, Carolina Ponce, Maria Teresa Pombo, Mora Amat, Maria Victoria Costanzo, Adrian Nervo, Jorge Nadal, Veronica Fabiano, Jose Loza, Carlos Martin Loza, Federico Colo, Chacon Reinaldo
PURPOSE: Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) expression may vary during tumoral progression. We aimed to describe and compare ER, PR, and HER2 expressions in primary breast tumors and synchronic axillary nodal metastases, and evaluate phenotypic correlations between them. METHODS: Patients were identified prospectively through surgical procedures between September 2013 and July 2016...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690652/prognostic-impact-of-progesterone-receptor-status-in-chinese-estrogen-receptor-positive-invasive-breast-cancer-patients
#19
Nan Yao, Zhenchuan Song, Xinle Wang, Shan Yang, Heng Song
PURPOSE: Estrogen receptor (ER) and progesterone receptor (PR) have been used as indicators of endocrine system status since the mid-1970s in the clinical management of breast cancer. The predictive role of ER in endocrine therapy is undisputed, but the prognostic value of PR is still debated. The aim of this study was to investigate the clinical characteristics and prognosis of ER positive breast cancer with different PR expression levels. METHODS: A population cohort of 3,030 primary invasive ER positive breast cancer patients from a single cancer center underwent surgery and received adjuvant endocrine therapy from 2004 to 2010...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690650/cd49f-can-act-as-a-biomarker-for-local-or-distant-recurrence-in-breast-cancer
#20
Feng Ye, Xiaorong Zhong, Yan Qiu, Libo Yang, Bing Wei, Zhang Zhang, Hong Bu
PURPOSE: Metastasis and local recurrence are the primary causes of treatment failure and patient death in breast cancer. The aim of this study was to validate a metastasis- and local recurrenceassociated biomarker for prognostic evaluation and planning treatment strategies. METHODS: Formalin-fixed, paraffin-embedded tissues from a cohort of 312 patients (all stage II and III) were used. The prevalence of CD49f(+) cells in the patients' tumors was analyzed and correlated with clinical characteristics to determine its prognostic and clinical implications...
June 2017: Journal of Breast Cancer
keyword
keyword
99768
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"